pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›LISDEXAMFETAMINE DIMESYLATE
drug
save

LISDEXAMFETAMINE DIMESYLATE

Marketedupdated 3mo ago
by Actavis Elizabeth LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval112 co-mentions · 56 sources
  • drugARYNTA97 co-mentions · 74 sources
  • tagSmall Molecule56 co-mentions · 56 sources
  • companySun Pharmaceutical Industries Ltd31 co-mentions · 10 sources
  • tagRecall17 co-mentions · 10 sources
  • companyOhm Laboratories Inc15 co-mentions · 8 sources
  • tagDrug Shortage8 co-mentions · 8 sources
  • companyApotex Corp1 co-mentions · 1 sources

all catalysts(5)

approval · 5
Aug 25, 2023
approval
3y ago
LISDEXAMFETAMINE DIMESYLATE — FDA approval
LISDEXAMFETAMINE DIMESYLATE
→
Jan 23, 2025
approval
2y ago
LISDEXAMFETAMINE DIMESYLATE — FDA approval
LISDEXAMFETAMINE DIMESYLATE
→
Jun 16, 2025
approval
1y ago
ARYNTA (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
LISDEXAMFETAMINE DIMESYLATE
→
Dec 22, 2025
approval
8mo ago
ARYNTA (LISDEXAMFETAMINE DIMESYLATE) — FDA approval
LISDEXAMFETAMINE DIMESYLATE
→
Mar 18, 2026
approval
5mo ago
LISDEXAMFETAMINE DIMESYLATE — FDA approval
LISDEXAMFETAMINE DIMESYLATE
→

Trials studying LISDEXAMFETAMINE DIMESYLATE

  • phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorderrecruitingn=105
  • phase4Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndromecompletedn=26
  • phase1To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.completedn=48
  • phase4Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autismcompletedn=48

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 16, 2040
~13.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Aug 30, 2040formulationUS 11576878
  • Apr 16, 2040formulationUS 12433859
  • Apr 16, 2040formulationUS 12582620

News(0)

no news has mentioned this drug yet

brand
LISDEXAMFETAMINE DIMESYLATE
generic
LISDEXAMFETAMINE DIMESYLATE
indication
Attention Deficit Hyperactivity Disorder (ADHD)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 28m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?